The potential role of alternative ADCs targeting the human trophoblast cell‐surface antigen 2 (TROP2) (NCT04152499) and MET351, 352 (NCT03859752) is also being evaluated in patients with lung cancers, potentially including NSCLCs with EGFR mutations or ALK rearrangements. This evidence concerns the gene ALK and lung cancer.